Bobbi Coffin is the Chief Growth Officer for Biodesix, where her personal mission of “helping cancer patients live the best lives possible” is the driving force behind her work in marketing, public relations, and commercial growth strategy development. Since 2015, Bobbi has launched 6 of the 8 non-invasive diagnostic tests in the Biodesix Lung Disease Portfolio, including the blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests. Additionally, Coffin added the GeneStrat NGS™ test to the blood- based IQLung™ strategy for lung cancer patients which integrates with the GeneStrat® ddPCR™ test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. In response to the global pandemic and virus that impacts the lung and causes COVID-19, Bobbi launched the WorkSafe program which included testing strategies for businesses using the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,).
Bobbi brings a depth of experience to the leadership team and is an accomplished marketer in healthcare, with over 25 years of expertise. Prior to joining Biodesix, Bobbi served as Vice President of Commercial Marketing and Strategy at Exact Sciences, a molecular diagnostics company with a focus on the early detection and prevention of colorectal cancer. From 2007 to 2013, Coffin was Vice President of Marketing at Precision Therapeutics, and from 1999 to 2006, she held the position of Senior Director of Marketing at Cytyc Corporation (now Hologic).
Bobbi holds a B.S. from the College of Business and Economics and the Perley Isaac Reed School of Journalism; both completed at West Virginia University and has served in board positions that support her personal mission of helping patients with cancer through diagnostic testing. Bobbi has served as an executive board member for multiple national advocacy and society groups, including the National Comprehensive Cancer Network Corporate Counsel (NCCN), the Society of GYN Oncology (SGO) Industry Board, and the Colon Cancer Foundation. Most recently, Bobbi is on the executive committee and Board of Directors for the Colorado Bioscience Association, supporting the growing bioscience workforce in the state of Colorado.